By Blake Adams, VP of Marketing, Florence
COVID-19 radically disrupted clinical trial operations and forced an acceleration of the transformation agendas leaders had in place pre-crisis. While clinical operations leaders understood the importance of harnessing technology to streamline processes and remotely connect clinical study stakeholders, the transformation timeline was gradual over the next five-plus years.
However coping measures to mitigate COVID disruptions will have a measurable impact on the industry and its shift to more substantial technology infrastructure.
While the acceleration of pre-crisis transformation agendas in clinical trial operations will be measurable, it will not leap to a 10+ year horizon. Instead, it will settle into a more manageable four-year future state: 2021 will now resemble the predictions for 2025.
This blog takes a deeper dive into these changes and how it will affect the industry.